The second-highest executive at Mylan (MYL) is the target of a widening civil investigation being conducted by dozens of states into allegations that numerous generic drug makers conspired to fix prices.

Attorneys general from 45 states want to add Rajiv Malik, the Mylan president and an executive director, to a lawsuit that was initially filed late last year. The original suit alleged six generic drug makers, including Mylan, colluded to set prices for two medicines. But an amended lawsuit — if approved by a federal court — would add another dozen companies and now cites 15 different drugs.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy